ANIP: ANI Pharmaceuticals Company Buyout Price

ANI Pharmaceuticals Corp - graphic logo of issuer ANIP

ANI Pharmaceuticals (ANIP) relies on stable demand for prescription drugs, which guarantees resilience to economic downturns and an absence of seasonality. A high degree of automation in packaging and dosing lines eliminates manual labor, ensuring product sterility. This chart of the market trend in monetary terms shows the company's valuation at 1869.42. Investors value the company for its supply reliability and high-quality niche developments.

ANIP (anipharmaceuticals.com) Total Company Value history from 11/23/2025 to 10/28/2026
Original product of ANI Pharmaceuticals

Stable income from niche generics at ANI Pharmaceuticals (ANIP) forms the foundation for valuing the business via the sum of market capitalization and net debt. By analyzing the enterprise value (EV), an investor determines the actual cost of acquiring the company, weighing this momentum against operating profit to identify asset overheating and minimize risks during market corrections.

Competitor analysis for ANI Pharmaceuticals

Business Value Haleon PLC HLN|Enterprise Value KVUE (Kenvue Corp)|VRNA: Company Buyout Price|Total Company Value Jyong Biotech Ltd (MENS)|LGND (ligand.com) - Full Business Value|Total Company Value Amneal AMRX|Full Business Value Perrigo Company PLC|Alvotech Corp (ALVO) - Enterprise Value|Value Adjusted for Debt and Cash Liquidia Inc. (LQDA)|Enterprise Value GLPG (Galapagos NV)|mannkindcorp.com - Enterprise Value|Total Company Value Amphastar Pharmaceuticals, Inc. (AMPH)|PCRX: Value Adjusted for Debt and Cash|SPRY (ARS Pharma) - Total Company Value|Theravance Corp (TBPH) - Real Price to Acquire Entire Company|AQST (Aquestive Therapeutics) - Enterprise Value|Enterprise Value scPharma (SCPH)|Tectonic Therapeutic, Inc. (TECX) - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash TNXP (Tonix Pharma)|SXTC: Total Company Value|EPRX - Total Enterprise Value|Real Price to Acquire Entire Company BioHarvest Sciences BHST|EXOZ - Aggregate Business Value|Enterprise Value oramed.com ORMP|Entera Bio (ENTX) - Value Adjusted for Debt and Cash|Enterprise Value HYFT (MindWalk)|Total Enterprise Value ABVC|Cumberland Pharmaceuticals (CPIX) - Total Company Value|Value Adjusted for Debt and Cash quantumbiopharma.com (QNTM)|Enterprise Value FGEN (FibroGen)|Telomir Pharmaceuticals Inc - Enterprise Value|Rani Therapeutics Inc (RANI) - Total Company Value|SNYR - Business Value|rallybio.com - Enterprise Value|Company Buyout Price Lexaria Bioscience Corp.|PULM - Real Price to Acquire Entire Company|Value Adjusted for Debt and Cash PTHL|APM - Total Company Value|Full Business Value Lyra Therapeutics Inc (LYRA)|Enterprise Value Impact BioMedical|Value Adjusted for Debt and Cash TNF Pharmaceuticals Inc. TNFA|cbdMD Corp - Enterprise Value|PRFX: Enterprise Value|Total Company Value altamiratherapeutics.com CYTO|LIPO (Lipella Pharma) - Value Adjusted for Debt and Cash|Total Company Value OPTN|Real Price to Acquire Entire Company pieris.com|Enterprise Value PROC|Enterprise Value Petros Pharmaceuticals Inc (PTPI)|Qilian International Holding Group Limited - Enterprise Value|Real Price to Acquire Entire Company ACELYRIN Inc. SLRN|TFFP (TFF Pharmaceuticals) - Enterprise Value